 | | Vol. 10.22 – 7 June, 2022 |
| |
|
|
| Researchers investigated de novo DNA methyltransferase 3A (DNMT3A) mutations in common peripheral T cell lymphoma (PTCL) entities, including angioimmunoblastic T cell lymphoma and novel molecular subtypes identified within PTCL-not otherwise specified (NOS).
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated oncostatin M (OSM)’s role in pathological events important for the neuro-inflammatory disorder multiple sclerosis (MS) and showed that OSM receptor expression was increased on circulating lymphocytes of MS patients, indicating their elevated responsiveness to OSM signaling.
[Acta Neuropathologica] |
|
|
|
| Scientists reported a trichohepatoenteric syndrome patient with SKIV2L mutations showing severe primary B cell immunodeficiency, hypogammaglobulinemia, and kappa-restricted plasma cell dyscrasia but normal T cell and NK cell function.
[Science Immunology] |
|
|
|
| Investigators showed that intestinal IL-25–activated group 2 innate lymphoid cells (ILC2s) created an innate cancer-permissive microenvironment.
[Science Immunology] |
|
|
|
| Researchers reported ex vivo expansion of human B cells with in vivo regulatory function. CD154-stimulation of human CD19+ B cells drove >900-fold expansion of IL-10+ B cells that was maintained in culture for 14 days.
[Nature Communications] |
|
|
|
| Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. In this open-label trial, ten patients with cutaneous sarcoidosis were treated with tofacitinib, a Janus kinase inhibitor.
[Nature Communications] |
|
|
|
| Scientists reported 77 common autoantibodies based on the protein microarray data obtained from probing 182 healthy individual sera on 7,653 human proteins and an additional 90 healthy individual sera on 1,666 human proteins.
[Cell Reports] |
|
|
|
| Investigators immunophenotyped blood samples of Parkinson’s disease (PD) patients for the presence of myeloid derived suppressor cells (MDSCs) and discovered that DAT+/TH+ monocytic MDSCs but not granulocytic MDSCs were increased, suggesting a targeted immune response to PD.
[npj Parkinson’s Disease] |
|
|
|
| Inverse opal 3D hydrogels consisting of poly(ethylene) glycol covalently combined with heparin were engineered to resemble the environment of lymph nodes, where T cells get activated and proliferate.
[Biomaterials Science] |
|
|
|
| The authors found the myeloid-derived suppressor cells had an immunosuppressive function by expanding FOXP3+ regulatory T cells and inhibiting CD4+ T cell proliferation in patients with sepsis.
[Frontiers in Immunology] |
|
|
|
| Researchers used induced pluripotent stem cells-derived brain endothelial-like cell transwell co-culture model to assess blood brain barrier extravasation of CAR-T based immunotherapies targeting U87MG human glioblastoma cells overexpressing the tumor-specific mutated protein EGFRvIII.
[Fluids and Barriers of the CNS] |
|
|
|
| The authors investigated the effect of macrophage-derived exosomal APN/CD13 on the induction of epithelial cell necrosis.
[Communications Biology] |
|
|
|
|
| Scientists highlight non-canonical targets in preclinical multiple sclerosis research with a focus on five highly promising areas: oligodendrocytes, the blood–brain barrier, metabolites and cellular metabolism, the coagulation system, and tolerance induction.
[Nature Reviews Drug Discovery] |
|
|
|
| The authors review the key features that underlie why NK cells are emerging as important new additions to the cancer therapeutic arsenal.
[Nature Reviews Immunology] |
|
|
|
| Investigators focus on the latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors.
[Trends in Immunology] |
|
|
|
|
| Asher Biotherapeutics announced that it has entered into a clinical trial collaboration and supply agreement with Merck for a planned Phase Ia/Ib dose escalation and expansion trial to evaluate AB248, Asher Bio’s novel investigational CD8-targeted interleukin 2.
[Asher Biotherapeutics] |
|
|
|
| Abu Dhabi Stem Cells Center will begin the recruitment and enrollment of 45 patients in the Phase I/II study to evaluate the safety and efficacy of a pioneering new technology, extracorporeal photopheresis, which will be used in the treatment of multiple sclerosis.
[Abu Dhabi Stem Cells Center (PR Newswire, Inc.)] |
|
|
|
| Novartis announced the FDA has granted accelerated approval for Kymriah® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
[Novartis] |
|
|
|
| Eureka Therapeutics, Inc. and City of Hope announced that City of Hope treated the first patient with GPC3-positive advanced hepatocellular carcinoma, the predominant type of liver cancer, with ECT204, an experimental T cell therapy.
[Eureka Therapeutics] |
|
|
|
|
| June 20 – 23, 2022
Seville, Spain |
|
|
|
|
|
| | Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| | China Medical University – Shenyang, China |
|
|
|
| | NHS Blood and Transplant – Oxford, England, United Kingdom |
|
|
|
| | Human Technopole – Milan, Italy |
|
|
|
| | Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
